Search for: rheumatoid arthritis methotrexate autoimmune disease biomarker gene expression GWAS HLA genes non-HLA genes
| ID | PMID | Title | PublicationDate | abstract |
|---|---|---|---|---|
| 2828451 | Neutrophil activation by IgE-containing circulating immune complexes of patients with conn | 1988 Jan | In an earlier study, we reported IgE-containing circulating immune complexes (CICs) in 66.6% of the patients with rheumatoid arthritis who were studied, especially in those with extra-articular manifestations. The present study was undertaken to examine the possible role of these immune complexes in inflammatory cell activation. Twelve patients with classic or definite rheumatoid arthritis, two with primary Sjögren's syndrome, and three patients with systemic lupus erythematosus were studied. Of these 17 patients, 10 were IgE-containing CIC positive, and seven patients were IgE-containing CIC negative. Polyethylene glycol-precipitated IgE-containing CICs and IgG-containing CICs of these patients were coated on plastic wells and incubated with suspensions of neutrophils. As a parameter of cell activation, superoxide release (SOR) was measured by cytochrome C reduction in the supernatant after 30, 60, and 90 minutes. There was a significant SOR up to 38% of the zymosan control when IgE-containing CICs were incubated with neutrophils. Furthermore, there was a significant correlation between the level of IgE-containing CICs and the amount of SOR, but not between the level of IgG-containing CICs and the amount of SOR. These results suggest a possible role for IgE-containing CICs in the activation of inflammatory cells in connective tissue diseases. | |
| 3449983 | Clinical reports on plasma exchange in the Kidney Center, Tokai University School of Medic | 1987 Mar | There were 72 patients (19 with hepatic failure, 10 with fulminant hepatitis, eight with paraquat poisoning, eight with rheumatoid arthritis, five with myasthenia gravis, four with hyperlipidemia, four with systemic arteriosclerosis including brain infarction, three with pemphigus vulgaris, two with multiple myeloma, two with systemic lupus erythematosus, two cases non-specific Ig-G antibody, two cases medication with an anticancer drug, one with multiple sclerosis, one with Crohn's disease with amyloid kidney and one with chronic myeloblastic leukemia) treated by plasma exchange in the Kidney Center, Tokai University School of Medicine from Jan. 1983 to Dec. 1986. We performed plasma exchange using fresh frozen plasma in 40 cases and Lactate-Ringer's solution containing albumin (4.0-5.0%) in 20 cases as the replacement fluid. In 17 cases, we performed double filtration plasma exchange with the recycle system and no replacement fluid. Although PE therapy did not constitute a basic therapy for hyperlipidemia, pemphigus vulgaris, rheumatoid arthritis, myasthenia gravis, and systemic lupus erythematosus, it was effective in relieving severe clinical symptoms. At the present time, conventional plasma exchange does not improve the survival rate of patients with hepatic failure and fulminant hepatitis. Developments of a new artificial liver support apparatus and identity of many toxic substances in hepatic failure are necessary. No hypotension, hypovolemic shock or other significant complications were experienced. | |
| 2597209 | Arthritis in nursing home residents. A validation of its prevalence and examination of its | 1989 Dec | We studied nursing home residents to validate the method used in national surveys for estimating the prevalence of arthritis, and to examine the impact of arthritis on institutionalization and on the physical function of residents. Five homes were studied using a 3-phase approach. Directors of nursing in each home classified residents (n = 629) with respect to the presence of arthritis and senile dementia. The presence of osteoarthritis or rheumatoid arthritis and their impacts on a resident's initial placement were separately assessed by a physician through a chart review of a stratified subsample. The physician also rated a resident's likelihood of returning to community living. Finally, the functional impact of arthritis was assessed by a physical therapist. The nurses' estimate of the prevalence of arthritis in this population was 23.33%, while the physician estimate was 23.03%. These results are consistent with the 24.6% prevalence found in a 1977 national survey. Arthritis itself was a major cause of nursing home placement in 15% of all residents without dementia. Among those without dementia who also had arthritis, arthritis was a major cause of institutionalization in 31%. None of the residents without dementia showed substantial potential for reintegration into the community. Controlling for age, residents with arthritis had more pain, were more likely to require assistance in functional tasks, and were more likely to use a wheelchair daily than were their fellow residents. Nevertheless, our results suggest that arthritis, despite its impact on function, in and of itself is not a major cause of nursing home placement or ongoing institutionalization. | |
| 1767078 | Current status of the medical treatment of children with juvenile rheumatoid arthritis. | 1991 Nov | Based on clinical experience and the aforementioned studies, a number of opinions can be entertained concerning the historically traditional conservative management of children with JRA. 1. Because the inflammatory changes of JRA on the bones and joints once established are irreversible in most children, there are ample theoretical reasons to start more effective therapy (if available) early. 2. Most of the currently available drugs control inflammation only partially or temporarily. 3. Most children stop taking the various SAARDS after approximately 2 years of disease because of lack of efficacy or the development of toxicity. 4. Whereas corticosteroids are the most potent and effective anti-inflammatory agents, long-term use in children, even in low dosage, is severely limited, especially by their effect on growth. 5. Methotrexate appears to be the most effective of the alternative agents and much safer than expected when used in the currently recommended protocol. 6. More effective therapy must await a better understanding of the pathogenesis of JRA, although currently available medications might be used more rationally by taking into consideration available pharmacologic studies. | |
| 1943688 | Alcaptonuria and ochronotic arthritis. | 1991 Feb | The rare hereditary metabolic disorder alcaptonuria is characterized by the inability to metabolize homogentisic acid, an intermediary compound in the catabolism of the aromatic amino acids phenylalanine and tyrosine. The essentially complete deficiency of homogentisic acid oxidase causes a striking accumulation of homogentisic acid and a derived melanin-like pigment in the connective tissues; the latter is termed ochronosis. Urinary homogentisic acid is oxidized rapidly and becomes a brown or black pigment if alkali is added. Older alcaptonurics have intensely pigmented (ochronotic) connective tissues, primarily the cartilaginous joint surfaces, ribs, intervertebral disks, ear cartilage, etc. They also have an unusual type of arthritis affecting the large weight-bearing joints, i.e. hips, knees and spine, but not the small joints of the hands and feet, as in rheumatoid arthritis. A mechanistic explanation for ochronotic arthritis has not been worked out, but it is clear that accumulation of homogentisic acid in the connective tissues directly or indirectly leads to the arthritic changes. A detailed analysis of the events leading to alcaptonuric arthritis should be worthwhile since it is a model form of arthritis secondary to a well-defined metabolic disorder that must persist for many years before the arthritic complications appear. Possibly other, more common types of arthritis, develop secondarily to metabolic disturbances that involve chemical mediators less obvious, or less easily detected, than homogentisic acid. | |
| 1931510 | Imaging of arthropathies and disorders of connective tissue. | 1991 Oct | The evolution of diagnostic imaging has been recently characterized by a wish for a better understanding of pathogenesis of diseases and by technologic progress. Many authors published papers reexamining old myths and old concepts of osteoarthritis. Correlations between clinical data, radiologic data, and MR findings have allowed better definition of the characteristics of osteoarthritis of the knee. MR imaging is of great value in evaluating rheumatoid arthritis in the early stages and in certain locations such as the cervical spine and temporomandibular joint. New imaging techniques, especially CT and MR imaging, are also useful for accurately diagnosing Andersson lesions and cauda equina syndrome in ankylosing spondylitis as well as sacroiliac joint abnormalities in Crohn's disease. | |
| 2655558 | Pediatric rehabilitation. 5. Joint and connective tissue diseases. | 1989 May | This self-directed learning module presents pertinent information about rehabilitation management of specific joint and connective tissue diseases affecting children. This section highlights juvenile rheumatoid arthritis, Lyme disease, rheumatic fever, hemophilia, dermatomyositis, polymyositis, systemic lupus erythematosus, and other forms of arthritis. It is a section of the chapter of pediatric rehabilitation for the Self-Directed Medical Knowledge Program Study Guide for practitioners and trainees in physical medicine and rehabilitation. | |
| 3566842 | Pharmacological investigations of the new antiinflammatory agent 2-(10,11-dihydro-10-oxodi | 1986 Dec | The preventive and therapeutic effects of 2-(10,11-dihydro-10-oxodibenzo [b,f]thiepin-2-yl)propionic acid (CN-100) on local and systemic changes of rats with adjuvant arthritis being used frequently as experimental model of rheumatoid arthritis were investigated in comparison with those of reference drugs, indometacin and pranoprofen. Preventively and therapeutically CN-100 showed potent inhibitory effects on adjuvant primary inflammation and secondary lesion. CN-100 also exerted an evident preventive effect on destruction of foot bone, improved the changes in organ weight, and stimulated weight gain. These effects were dose-dependent, and the effects at 5.0 mg/kg were almost the same as those of indometacin and pranoprofen at 1.25 and 2.5 mg/kg, respectively. The mode of action of CN-100 resembled that of reference compounds. Although CN-100 improved the change in albumin/globulin ratio, which was a parameter of systemic inflammatory reactions, the effect was more remarkable in therapeutic administration than in preventive one. This suggests that CN-100 is suitable for clinical application. | |
| 2677173 | [Production of rheumatoid factor-like substance and arthritic findings in knees of mice im | 1989 May | Four strains of mice (A. SW, B10. D2, C57BL/6, DBA/1J) were immunized by subcutaneous injections of heat-killed E. coli 0: 14. After single or multiple immunizations, histologic sections of knee joints and a serum rheumatoid factor-like substance (RFLS) at different time intervals were studied. Immunized A. SW. mice developed hyperplasia of synovial lining cells (25 out of 49 knees) and pannus (9 out of 49 knees) which was significantly higher rate than control. A serum rheumatoid factor-like substance (RFLS) was detected in B10. D2 and C57BL/6 mice by using RAHA test and enzyme-linked immunosorbent assay. Serum IgM-RFLS was positive in all B10. D2 mice (11 of 11 mice) immunized for 24 weeks. The incidence of serum IgM-RFLS positive mice in C57BL/6 immunized for 40 weeks (3 of 4 mice) was significantly higher than in control (p less than 0.05). Production of serum RFLS was not recognized in a single-immunized group of B10. D2 mice on statistical evaluation. These findings provided evidence that arthritis was developed in multiple-immunized groups of A. SW mice and RFLS was produced in multiple-immunized groups of B10. D2 and C57BL/6 mice. In addition, these findings suggested that multiple-immunization was necessary for the production of RFLS. | |
| 2497986 | [The effect of a gold complex on experimental arthritis induced by immunization with type | 1989 Jan 6 | Gold complexes are used in the treatment of rheumatoid arthritis for some 60 years by now. The authors used therefore a gold complex, sodium aurothiosulphate (ATSS) to influence the experimental model of arthritis induced by immunization with type II collagen in laboratory rats. To the first group of laboratory rats ATSS was administered concurrently with the first immunization dose, to the second group with the second immunization dose and to the third group in the course of arthritis. ATSS was administered to individual groups every week by the i. m. route, 20 mg/kg body weight. In all three groups a reduction of arthritic symptoms was observed, however, in group three to a much lesser extent than in groups one and two. The results of the experiment indicate clearly that ATSS was able to suppress the development of collagen induced arthritis, if administered not later than with the second immunization dose. As the formation of antibodies against type II collagen was not suppressed, it may be assumed that the activation of the complement system was blocked by the bond of the gold complex with the C1q component. It has been proved already previously that the interaction of C1q with gold complexes is very rapid. | |
| 3497809 | Milestones in anti-inflammatory therapy. | 1987 | The anti-inflammatory era opened with aspirin, which for decades was the first-line treatment for rheumatoid arthritis. Striking advances have occurred in recent years with the introduction of propionic acid derivatives like ibuprofen and once-a-day drugs like piroxicam. The class now includes a range of drugs with properties suited to the range of clinical indications presented by rheumatic disorders. Anti-inflammatory drugs are now and will continue to be the mainstay of symptomatic therapy for arthritis. | |
| 1865576 | A case of maternal subclinical Sjögren's syndrome associated with congenital heart block. | 1991 Jan | A case of subclinical Sjögren's syndrome was diagnosed when the patient delivered a baby with SSA antibody-positive congenital heart block (CHB). The mother had been asymptomatic throughout her life. The laboratory findings including sialography, lip biopsy, Schirmer's test and a Rose-Bengal test showed Sjögren's syndrome. Such an asymptomatic case is termed subclinical Sjögren's syndrome. Thus, it was important to investigate an asymptomatic mother who delivers a SSA antibody-positive CHB baby. | |
| 2585401 | The presence of Sjögren's syndrome is a major determinant of the pattern of interstitial | 1989 Aug | A number of patients with scleroderma, Sjögren's syndrome and other connective tissue diseases (CTD) were assessed to ascertain the prevalence of respiratory abnormalities as defined by bronchoalveolar lavage (BAL), standard respiratory function studies and gallium scan of the lung, and the relationship of these abnormalities to the presence or absence of dyspnea. These results suggest that respiratory symptoms are very common in CTD and in scleroderma, particularly if Sjögren's syndrome is also present. Our findings also suggest the presence of 2 patterns of interstitial lung involvement in scleroderma. In scleroderma alone this appears to be characterized by the presence of increased neutrophil proportions in the BAL, decreased DLCO, and no increase in gallium uptake within the lung. Where scleroderma is associated with Sjögren's syndrome, there is an increase in the proportion of lymphocytes in the BAL and respiratory symptoms are very prominent, the latter associated with an increase in gallium uptake within the lung. This suggests that Sjögren's is a major determinant of the pattern of interstitial lung disease seen in CTD. | |
| 2543732 | Detection of Epstein-Barr virus DNA by polymerase chain reaction in blood and tissue biops | 1989 Jun 1 | Polymerase chain reaction has been used to detect increased levels of EBV DNA in salivary gland (SG) biopsies and PBL from patients with Sjogren's syndrome (SS). These results suggest that EBV, which has a normal site of latency in a small number of SG epithelial cells, may be reactivated in SS patients and provide a target for immune attack. The great sensitivity of polymerase chain reaction (PCR) and the ability to analyze very small tissue biopsies (37) make this technique well suited for clinical diagnosis. Specific methods to prevent artefactual contamination of tissue biopsy DNA with viral DNA of other samples (i.e., lyophilization of samples before DNA extraction) and the use of an internal positive control (i.e., inclusion of primers for a single copy human gene) during PCR amplification are presented. Since EBV reactivation occurs with markedly increased frequency in patients with lymphoproliferative and immunodeficiency diseases, as well as transplant recipients receiving cyclosporin A (10), rapid methods of viral detection such as PCR may allow better monitoring of medications and early detection of EBV-related lymphomas that may arise in these patients. | |
| 2019285 | The role of oil and agalactosyl IgG in the induction of arthritis in rodent models. | 1991 Apr | The proportion of agalactosyl IgG [Gal(O)] is raised in human rheumatoid arthritis and tuberculosis. We report here that injection of pristane into the peritoneal cavities of mice on days 0 and 50, which is known to induce plasmacytomas and arthritis, also induced a rise in the proportion of Gal(O), correlating with a simultaneous rise in the level of IgG antibody binding to the 65-kDa heat-shock protein of Mycobacterium bovis (hsp65). Arthritis developed in a proportion of those CBA/Igb mice with the highest percentage of Gal(O). Pretreatment with 50 micrograms of recombinant mycobacterial hsp65 intraperitoneal (i.p.) on day -10, or with 500 rad irradiation on day -2 before the first of the two injections of pristane reduced the incidence of arthritis from 24% in control animals, to 5.3% and 0.4%, respectively. The reduced incidence of disease correlated with smaller rises in the % Gal(O) at 50-75 days, although levels at 150-200 days were not affected. The arthritogenic effect of oil was not confined to the pristane model, since a single i.p. injection of oil 21 days before immunizing DBA/1 mice with type II collagen reduced the mean day of onset of this arthritis, [which we have previously shown to correlate with raised % Gal(O)], from 38 to 15 days (p less than 0.001). One interpretation is that an autoimmunogenic stimulus, given when % Gal(O) is raised, is more likely to evoke disease. Since oil granulomata are known to secrete interleukin 6, which has B cell-regulatory properties and is secreted by rheumatoid synovial cells, we tested sera from interleukin 6-transgenic mice, and found a strikingly raised percentage of Gal(O). We suggest, therefore, that the role of oil in the induction of arthritis is the dysregulation of cytokine release of which a raised percentage of Gal(O) may be a direct or indirect consequence, associated with an increased susceptibility to autoimmunogenic stimuli. | |
| 3090824 | The diagnostic usefulness of measuring antineutrophil antibodies in neutropenic patients. | 1986 | We prospectively evaluated the usefulness of measuring antineutrophil (PMN) antibodies in patients with neutropenia by a sensitive immunoassay. The result of the immunoassay were compared to a standard leukoagglutination test. Thirty-two patients with neutropenia were studied. The mean value (+/- 1 SD) for PMN-bound IgG for 43 normal controls was 121 +/- 29 fg/PHN. All fifteen patients with immune neutropenia had elevated plasma levels of anti-PMN antibody (191-2,000 fg/PMN). The leukoagglutination assay was positive in 10 of these 15 patients. In 17 patients with nonimmune neutropenia, the mean value (+/- 1 SD) for PMN-bound IgG was 120 +/- 22 fg. Seventeen patients with sero-positive rheumatoid arthritis but normal PMN counts were also studied. These patients' plasmas bound 447 +/- (1 SD) 201 fg IgG/PMN. The leukoagglutination test was negative in these patients. Our study shows that the immunoassay is more sensitive than leukoagglutination testing for diagnosing immune neutropenia. Nonimmune, neutropenic patients' plasmas showed no increased reactivity. In nonneutropenic patients who have high titers of rheumatoid factor, immunoreactivity against PMN is measured by the immunoassay, but not by leukoagglutination testing. Binding assays may be more sensitive than leukoagglutination testing for measuring anti-PMN antibodies; however, in some cases, specificity of such testing may be increased with leukoagglutination testing. | |
| 2379048 | Arthritis mutilans, tumoral calcinosis, Raynaud's phenomenon and Sjögren's syndrome. | 1990 Aug | We report a female patient who over 25 years developed a progressive deforming arthropathy involving both hands without anatomical or functional abnormalities of other joints. Raynaud's phenomenon, lung fibrosis and Sjögren's syndrome. She had multiple soft tissue and periarticular calcification particularly evident in the lower extremities, shoulders, hands, fingers and back. | |
| 2788824 | Exocrinopathy resembling Sjögren's syndrome in HTLV-1 tax transgenic mice. | 1989 Sep 7 | Human T-cell leukaemia virus 1 (HTLV-1) is a retrovirus aetiologically associated with adult T-cell leukaemia (ATL), tropical spastic paraparesis (TSP) and possibly multiple sclerosis (MS) in humans. Three founder lines of transgenic mice containing the HTLV-1 tax gene under the control of the viral long terminal repeat (LTR) have previously been shown to develop neurofibromas. Further analysis of these animals has now revealed that they also develop an exocrinopathy involving the salivary and lachrymal glands. This pathology resembles Sjögren's syndrome, a disease of presumed autoimmune aetiology, features of which are sometimes reported in HTLV-1 associated conditions. Mice with an HTLV-1 tax transgene might be a useful model for studying the development of Sjögren-syndrome-like pathology. | |
| 2789651 | Rose bengal score--a possible key parameter when evaluating disease level and progression | 1989 Aug | The rose bengal score is one of the most commonly used tests for evaluation of ocular surface epithelial damage. The test is used in most Sjögren's syndrome criteria. We examined 24 female and four male patients with primary Sjögren's syndrome (primary SS) in order to evaluate possible correlation between the various tests for keratoconjuncivitis sicca (KCS), and for possible correlations to xerostomia and p-IgG levels. Among the KCS tests a high rose bengal score appeared to be the key parameter, being correlated to low break-up time (P less than 0.01), low tear lysozyme (P less than 0.01), appearance of snake-like chromatin in conjunctival imprints (P less than 0.05), low sialometry (P greater than 0.01) and high p-IgG (P less than 0.01). We followed another group of patients with primary SS (30 females and four males) for a mean period of 53 (range 27-76) months. The patients were divided according to their initial response to systemic treatment with bromhexine. KCS parametres and p-IgG were measured repeatedly during the observation period. Patients responding to and continuously treated with bromhexine (2/3 of patients) improved significantly (P less than 0.05) in rose bengal score, but had increasing levels of p-IgG. Non-responders kept their low tear-production rate and had also increasing p-IgG levels. However, when subdivided according to p-IgG level, the group of patients with relatively low p-IgG improved in rose begal score, whereas the high p-IgG-group increased in rose bengal score. The rose bengal score appears to be a useful key parameter when evaluating disease level and progression. | |
| 3257371 | The relationship between anti-Ro (SS-A) antibody-positive Sjögren's syndrome and anti-Ro | 1988 Jan | Ten Ro(SS-A) antibody-positive patients with Sjögren's syndrome and lupus erythematosus are described. These patients have a disease process characterized by the frequent appearance of annular polycyclic lupus lesions of subacute cutaneous lupus erythematosus (SCLE), as well as neurologic and pulmonary disease. The Ro(SS-A) antibody-positive patients may have Sjögren's syndrome for many years and then suddenly develop lupus erythematosus, and vice versa. These studies demonstrate that the patient with Ro(SS-A) antibody may exhibit a dynamic clinical disease expression over time and that there is a closer pathologic relationship between Sjögren's syndrome and SCLE in these patients with Ro(SS-A)-antibody than has previously been appreciated. Furthermore, Ro(SS-A)-positive patients with Sjögren's syndrome and lupus erythematosus appear to have a much more guarded prognosis than those Ro(SS-A)-positive lupus patients described under the classifications of antinuclear antibody-negative lupus erythematosus and SCLE. |